 Sangamo Therapeutics Inc NASDAQ: SGMO announced preliminary results from the Phase 12 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene therapy candidate for Fabry disease. As of the September 17, 2021 cutoff date, results from the four patients treated in the first two dose cohorts 0.5e13 vgkg and 1e13 vgkg showed that the gene therapy was generally well tolerated. 